GlassScriptPhysician profile
John R Hansen
NPI 1073521977
$13,008.43
in general payments reported to CMS, 2019-2025
62 companies · $1,751 in 2025
The $1,751 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,555 · 2020: $1,174 · 2021: $2,043 · 2022: $2,215 · 2023: $2,105 · 2024: $2,165 · 2025: $1,751.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,021.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,021.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,770.15 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $1,768.10 | 2020-2025 | |
| Novo Nordisk INC | $1,504.74 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,451.03 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $969.58 | 2019-2025 | |
| Antares Pharma, INC. | $599.14 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Amgen INC. | $493.45 | 2019-2025 | Evenity, Prolia, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $459.15 | 2019-2024 | Jardiance |
| Amarin Pharma, INC. | $351.27 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $291.41 | 2019-2024 | Xifaxan |
| Glaxosmithkline, LLC. | $253.25 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbott Laboratories | $252.29 | 2021-2025 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $219.55 | 2020-2023 | Xarelto |
| Merck Sharp & Dohme LLC | $174.45 | 2019-2024 | Capvaxive, Gardasil 9, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $170.28 | 2022-2024 |
Show all 62 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Hansen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.